Unicycive Therapeutics, Inc. Faces Lawsuit for Securities Law Breaches - Investors Urged to Reach Out to Levi & Korsinsky by October 14, 2025 to Explore Their Rights - UNCY | Intellectia.AI
Unicycive Therapeutics, Inc. Faces Lawsuit for Securities Law Breaches - Investors Urged to Reach Out to Levi & Korsinsky by October 14, 2025 to Explore Their Rights - UNCY
Written by Emily J. Thompson, Senior Investment Analyst
Class Action Lawsuit Announcement: Levi & Korsinsky, LLP has announced a class action securities lawsuit on behalf of investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) due to alleged securities fraud occurring between March 29, 2024, and June 27, 2025.
Allegations Against the Company: The lawsuit claims that Unicycive made false statements regarding its ability to meet FDA manufacturing compliance requirements and overstated the regulatory prospects of its new drug application, leading to misleading public statements.
Investor Participation Details: Investors who suffered losses during the specified period have until October 14, 2025, to request appointment as lead plaintiff, with no costs or obligations required to participate in the lawsuit.
Firm's Credentials: Levi & Korsinsky has a strong track record in securities litigation, having secured significant compensation for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S.
UNCY
$5.88+Infinity%1D
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.880
Low
21.00
Averages
36.60
High
60.00
Current: 5.880
Low
21.00
Averages
36.60
High
60.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
maintain
$9 -> $22
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9 -> $22
2025-10-29
maintain
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.
Benchmark
Speculative Buy
maintain
$3 -> $21
2025-09-15
Reason
Benchmark
Price Target
$3 -> $21
2025-09-15
maintain
Speculative Buy
Reason
Benchmark raised the firm's price target on Unicycive Therapeutics to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm's new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.
Lucid Capital
Elemer Piros
Buy
initiated
$12
2025-06-04
Reason
Lucid Capital
Elemer Piros
Price Target
$12
2025-06-04
initiated
Buy
Reason
H.C. Wainwright
Buy
initiated
$9
2025-05-27
Reason
H.C. Wainwright
Price Target
$9
2025-05-27
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Unicycive Therapeutics with a Buy rating and $9 price target. Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company's leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
